CClinicalTrials.gg
CompletedNCT07399431Updated Sep 16, 2026

Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia

An interventional study of Theta Burst Stimulation and Cognitive Behavioral Therapy in Methamphetamine Use Disorder, Theta Burst Stimulation and Transcranial Magnetic Stimulation, sponsored by Universitas Indonesia. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Universitas Indonesia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

Methamphetamine use disorder (MUD) remains a major public health concern in Indonesia, with limited effective treatment options and high relapse rates. Theta Burst Stimulation (TBS) has emerged as a promising adjunctive intervention for reducing craving and improving clinical outcomes. This trial aims to evaluate the efficacy and safety of TBS for MUD. A RCT of 20 subjects was conducted to evalute the efficacy and safety of TBS as an adjunctive treatment to CBT in managing MUD.

02

Conditions studied

  • Methamphetamine Use Disorder
  • Theta Burst Stimulation
  • Transcranial Magnetic Stimulation

Keywords

  • Methamphetamine Use Disorder
  • Theta Burst Stimulation
  • Cognitive Behavioral Therapy
  • Transcranial Magnetic Stimulation
03

In context

Lead sponsor

Universitas Indonesia is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects aged 18-59 years old
  • Subjects diagnosed with methamphetamine use disorder without having undergone treatment, whether psychotherapy and/or psychopharmacological modalities
  • Subjects are able to read and write

Exclusion criteria

Exclusion Criteria:

  • Subjects with severe thought process disorders, impaired perception, restless condition, severe neurological disorders, history of neuromodulation,
  • Subjects refused to participate in the study
  • Subjects who are pregnant
  • Subjects who have radioactive implants
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    TBS and CBT

    During 12 days of intervention, the participants underwent 10 sessions of TBS and 12 sessions for CBT.

    Device: Theta Burst Stimulation · Behavioral: Cognitive Behavioral Therapy

  • Sham comparator
    Sham and CBT

    During 12 days of intervention, the participants underwent 10 sessions of sham TBS and 12 sessions of CBT.

    Device: Theta Burst Stimulation · Behavioral: Cognitive Behavioral Therapy

Interventions

  • DeviceTheta Burst Stimulation

    A randomized controlled trial (RCT) of 20 participants underwent TBS and CBT intervention for MUD.

    Also known as: TBS, Transcranial Magnetic Stimulation, TMS

  • BehavioralCognitive Behavioral Therapy

    The cognitive behavioral therapy (CBT) for methamphetamine use disorder (MUD) was conducted in 12 sessions (1 session per day). We utilized the module adapted from the Indonesia Drug Addiction and Relapse Prevention Program (Indo-DARPP) for MUD. The CBT was delivered by trained psychiatrist in group CBT setting.

    Also known as: CBT

06

What researchers measure

Primary outcomes

  1. Improvement in craving for methamphetamine

    Cue-induced craving was measured with Visual Analog Scale (VAS) where the patient told to indicate their point of craving in a 100 mm line. The scale ranged from 0 to 10, with higher scores indicated higher craving.

    Time frame: Baseline (T1), day 3 (T2), day 5 (T3), day 8 (T4), and day 10 (T5)

  2. Improvement in craving (tonic) for methamphetamine

    Tonic or baseline craving was measured using the Questionnaire for Smoking Urges modified for Methamphetamine (QSU-M) in Indonesian version. The questions were self-filled by the participants to identify their level of craving. The QSU-M is a 7-point Likert Scale (1 was strongly disagree and 7 was strongly agree) with the higher total scores indicating higher tonic craving. The total minimum score was 10 while the maximum score was 70.

    Time frame: Baseline (T1), day 3 (T2), day 5 (T3), day 8 (T4), and day 10 (T5)

  3. Improvement in clinical severity

    The clinical severity was measured using the Clinical Global Impression - Severity by the psychiatrist based on the patient's condition during the day of examination. CGI is a clinician-rated instrument used to assess the patient's condition based on clinical judgment. CGI mainly rates the severity of illness assessed using a 7-point Likert scale, ranges from 1 (normal) to 7 (among the most extremely ill). Higher score indicated higher severity of addiction-related illness.

    Time frame: Baseline (T1), day 3 (T2), day 5 (T3), day 8 (T4), and day 10 (T5)

Secondary outcomes

  1. Improvement in Addiction Severity

    Addiction Severity Index (ASI) assessed the severity of a person's addiction, through multiple domains; medical, occupational, alcohol usage, substance use, law, family/social and mental status domains. The analysis utilized composite scores of relevant questions. Higher scores indicated higher severity. The minimum composite score for each domain was 0 while the maximum score was 1.

    Time frame: Baseline (T1) and Post-Intervention Day 12 (T6)

  2. Improvement in Depressive Symptoms

    The Patient Health Questionnaire-9 (PHQ-9) assessed the severity of depressive symptoms, with higher scores indicating higher severity. PHQ-9 is a 9 item with 3-point Likert scale with 0 indicates no presence of symptoms and indicates higher frequency of depression symptoms (nearly every day). The higher total scores indicates higher severity of depression, with the minimum total score of 0 and the maximum score of 27.

    Time frame: Baseline (T1) and Post-Intervention Day 12 (T6)

  3. Improvement in Motivation to Change

    University of Rhode Island Change Assessment (URICA) assessed a person's readiness for change, with scores divided into four subscales: pre-contemplation, contemplation, action and maintenance. URICA is a five-point Likert scale consisting of 32 questions, ranges from 1 (strongly disagree) to 5 (strongly agree). The minimum averaged score per subscale was 1 while the maximum score was 5. The calculation was done with the formula as follow: (averaged contemplation + averaged action + averaged maintenance)/averaged pre-contemplation. Higher overall score indicated higher stage of change.

    Time frame: Baseline (T1) and Post-Intervention Day 12 (T6)

  4. Improvement in Impulsivity

    The Barratt Impulsiveness Scale version 11 (BIS-11) assesed impulsive attitudes and behaviors. BIS-11 was a four-point Likert scales of 30 items, ranged from 1 (never/very rarely), 2 (rarely), 3 (often), and 4 (almost always). The total scores ranged from 30 to 120. Higher scores indicate higher overall impulsivity.

    Time frame: Baseline (T1) and Post-Intervention Day 12 (T6)

  5. Improvement in Sleep Quality

    The Pittsburgh Sleep Quality Index (PSQI) assessed sleep quality, measuring subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction. PSQI consisted of different segments of questions from sleep duration, habitual efficiency, and symptoms of sleeping problems. The symptoms were measured in 4-point Likert scale where 0 indicated no difficulty and 3 indicated high difficulty of sleeping. This instrument consisted of 19 questions, yielding a global score from 0 to 21. A higher total score indicated poor sleep quality.

    Time frame: Baseline (T1) and Post-Intervention Day 12 (T6)

07

Study locations

1 site
  • Universitas Indonesia
    Jakarta Pusat, Jakarta Special Capital Region 10430, Indonesia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07399431
Lead sponsor
Universitas Indonesia
Responsible party
Kristiana Siste (Dr. dr. Kristiana Siste, Sp.KJ(K) - Head of Department of Psychiatry, Cipto Mangunkusumo General Hospital, Universitas Indonesia) — Principal investigator
First posted
Feb 10, 2026
Start date
Mar 23, 2026
Primary completion
Jun 10, 2026
Completion
Jun 12, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion